

Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric A β in primary cell culture

Hafiz Mohammad Abdul,¹ Irfan Baig,^{1,2} Harry LeVine 3rd,^{1,2} Rodney P. Guttman^{1,3} and Christopher M. Norris^{1,4}

¹The Sanders-Brown Center on Aging, ²Department of Molecular and Cellular Biochemistry, ³Graduate Center for Gerontology, and ⁴Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, KY 40536, USA

Summary

Recent reports demonstrate that the activation and interaction of the protease calpain (CP) and the protein phosphatase calcineurin (CN) are elevated in the late stages of Alzheimer's disease (AD). However, the extent to which CPs and CN interact during earlier stages of disease progression remains unknown. Here, we investigated CP and CN protein levels in cytosolic, nuclear, and membrane fractions prepared from human postmortem hippocampal tissue from aged non-demented subjects, and subjects diagnosed with mild cognitive impairment (MCI). The results revealed a parallel increase in CP I and the 48 kDa CN- α (Δ CN- α 48) proteolytic fragment in cytosolic fractions during MCI. In primary rat hippocampal cultures, CP-dependent proteolysis and activation of CN was stimulated by application of oligomeric A β _(1–42) peptides. Deleterious effects of A β on neuronal morphology were reduced by blockade of either CP or CN. NMDA-type glutamate receptors, which help regulate cognition and neuronal viability, and are modulated by CPs and CN, were also investigated in human hippocampus. Relative to controls, MCI subjects showed significantly greater proteolytic levels of the NR2B subunit. Within subjects, the extent of NR2B proteolysis was strongly correlated with the generation of Δ CN- α 48 in the cytosol. A similar proteolytic pattern for NR2B was also observed in primary rat hippocampal cultures treated with oligomeric A β and prevented by inhibition of CP or CN. Together, the results demonstrate that the activation and interaction of CPs and CN are increased early in cognitive decline associated

with AD and may help drive other pathologic processes during disease progression.

Key words: Ca²⁺; Alzheimer's disease; amyloid; mild cognitive impairment; calcineurin; calpain; NMDA receptors.

Introduction

Fundamental to the Ca²⁺ hypothesis of aging is the presumption that Ca²⁺ dysregulation increases vulnerability to Alzheimer's disease (AD), and other age-related neurologic disorders (Toescu *et al.*, 2004; Thibault *et al.*, 2007; Toescu & Verkhatsky, 2007). While cumulative evidence from numerous studies on amyloid-bearing transgenic mice and/or amyloid-treated nervous tissue has built a compelling case for the Ca²⁺ hypothesis (Canzoniero & Snider, 2005; Bezprozvanny & Mattson, 2008; Green & LaFerla, 2008; Small, 2009), the link between Ca²⁺ and disease progression in human studies has been somewhat weaker, as comparisons are generally made between subjects at polar ends of the disease spectrum (i.e., between non-demented pathologically-normal subjects and subjects with pathologically-confirmed AD). Based on these comparisons, it remains unclear as to whether Ca²⁺ dysregulation is an antecedent or a consequence (or both), of AD pathology. If changes in Ca²⁺ regulation help drive pathology, as set forth by the Ca²⁺ hypothesis, then alterations in Ca²⁺ signaling mechanisms should emerge in the early stages of the disease, when signs of mild cognitive impairment (MCI) are first diagnosed. It is notable that clinical MCI subjects show several anatomical and biochemical anomalies in the hippocampus consistent with Ca²⁺ dysregulation, including loss of synapses and/or synaptic proteins (Scheff *et al.*, 2006, 2007; Sultana *et al.*, 2010) and neural atrophy (Apostolova *et al.*, 2010). However, few studies have directly investigated Ca²⁺ signaling mechanisms in human MCI brain tissue.

The Ca²⁺-dependent protease calpain (CP) and the Ca²⁺/calmodulin-dependent protein phosphatase calcineurin (CN) play critical roles in regulating neuronal structure and function, and exhibit elevated activity levels in AD brain tissue and/or in experimental models of AD (Saito *et al.*, 1993; Kuwako *et al.*, 2002; Liu *et al.*, 2005; Norris *et al.*, 2005; Dineley *et al.*, 2007; Vaisid *et al.*, 2007; Kuchibhotla *et al.*, 2008; Rao *et al.*, 2008; Reese *et al.*, 2008; Abdul *et al.*, 2009; Wu *et al.*, 2010). In the last 10 years, it has become increasingly clear that extensive interactions between CP and CN lead to diminished neuronal function and viability (See & Loeffler, 2001; Wu *et al.*, 2004; Shioda *et al.*, 2006; Wu *et al.*, 2007; Huang *et al.*, 2010). During severe

Correspondence

Dr Christopher M. Norris, University of Kentucky College of Medicine, 131 Sanders-Brown Building, 800 South Limestone Street, Lexington, KY 40536. Tel.: 1-859-257-1412; fax: 859-323-2866; e-mail: cnorr2@email.uky.edu

Accepted for publication 7 October 2010

Ca²⁺ dysregulation, for instance, CP binds to and proteolyzes the 60 kDa CN catalytic subunit (CN-A), converting it to several high-activity fragments (Wu *et al.*, 2004). The most commonly studied fragment has a molecular weight of 45–48 kDa (ΔCN-A48) and completely lacks a critical C-terminal auto-inhibitory domain (AID) responsible for limiting CN activity when Ca²⁺/calmodulin levels are low (Tallant *et al.*, 1988; Wang *et al.*, 1989). Without the AID, ΔCN-A48 is active even after intracellular Ca²⁺ recovers to basal levels. A larger, 57 kDa CP-generated fragment (ΔCN-A57) has also been described. Although the AID is largely intact in the ΔCN-A57 species, this fragment, like ΔCN-A48, shows greater basal activity compared to full-length CN-A (Liu *et al.*, 2005).

Recent studies have reported increased temporal cortex levels for both ΔCN-Aα48 and ΔCN-Aα57 in patients with confirmed AD (Liu *et al.*, 2005; Wu *et al.*, 2010). The purpose of the present study was to investigate whether these changes are apparent when clinical memory deficits and neuroanatomical anomalies first appear (i.e., during MCI). We show for the first time that CP and ΔCN-Aα48 levels are significantly greater in human hippocampal cytosolic fractions prepared from MCI relative to age-matched control subjects. Importantly, CP and ΔCN-Aα48 levels were positively correlated to one another within subjects and linked to altered proteolytic processing of the NR2B subunit of the NMDA receptor. Using rat primary hippocampal cultures, we also offer the first evidence that CP-mediated proteolysis and activation of CN is a critical mechanism through which oligomeric Aβ_(1–42) peptides cause neurodegeneration. The results provide important support for the Ca²⁺ hypothesis of aging and AD.

Results

Increase in ‘activated’ calpain I levels with MCI

Earlier studies by other investigators suggest that, with Ca²⁺ dysregulation, CP I is converted from an inactive 80 kDa protein to an activated 76 kDa fragment through autoproteolysis. Presently, however, little information is available regarding the levels of activated CP I in human subjects during putative early stages of AD, such as MCI. To address this issue, we used Western blot to detect and quantify CP I protein levels in cytosolic and nuclear fractions from postmortem human hippocampal tissue of ten MCI and ten age-matched control subjects (see Table 1 for subject information). As shown in Fig. 1A, CP I commonly exhibited two major bands (80 and 76 kDa) in both subject groups. A few samples in each group also showed another minor band at

78 kDa. Similar banding patterns for CP I in human brain tissue have been shown in several earlier studies (Saito *et al.*, 1993; Veeranna *et al.*, 2004; Liu *et al.*, 2005; Marcum *et al.*, 2005). As shown in Fig. 1B, the 76 kDa-to-80 kDa ratio for CP I was more than two fold greater in the MCI subjects (*P* < 0.01; Fig. 1B), suggesting that CP I activity is increased during early stages of clinical cognitive decline. MCI subjects also showed slightly greater nuclear CP I levels, however, this difference was not significant.

Selective changes in CN proteolysis with MCI

CN is among the many targets of CP-mediated proteolysis in central nervous system. Proteolysis of CN by CP can result in the removal of the AID from the CN-A subunit, yielding a 45–48 kDa proteolytic fragment with high catalytic activity (Tallant *et al.*, 1988; Wang *et al.*, 1989). A similar 48 kDa fragment was recently found at elevated levels in nuclear tissue fractions harvested from subjects with severe AD (Wu *et al.*, 2010). And in an earlier study, Liu *et al.*, 2005 revealed an increase in the proteolysis of CN to a highly active 57 kDa fragment in late stage AD brain samples. Last year, we reported that CN signaling in human hippocampus was elevated early in cognitive decline and continued to rise as dementia worsened during the later stages of AD (Abdul *et al.*, 2009). Together, these results, along with evidence for increased CP I activation levels in MCI (Fig. 1), suggest that elevated CN signaling in early AD may be due to CP-mediated proteolysis. We therefore investigated this possibility in the same tissue fractions shown above (Fig. 1) using anti-CN-A antibodies that recognize the full length and truncated fragments of the CN-Aα and CN-Aβ isoforms.

As shown in Fig. 2A, both CN-A isoforms (α and β) in human hippocampus were detected as four primary bands with molecular weights of ~60, ~57, ~48, and ~37 kDa. The 60 kDa

Table 1 Subject information

| Groups | <i>n</i> | Male/Female | Age | Postmortem | MMSE |
|---------|----------|-------------|--------------|------------------|--------------|
| | | | mean ± SEM | autopsy interval | |
| | | | mean ± SEM | mean ± SEM | mean ± SEM |
| Control | 10 | 3/7 | 89.75 ± 1.87 | 3.06 ± 0.25 | 28.75 ± 0.43 |
| MCI | 10 | 6/4 | 89.2 ± 1.65 | 3.03 ± 0.28 | 24.10 ± 1.21 |




Fig. 1 Increase in activated form of calpain I with MCI. (A) Representative western blot for CP I in cytosolic (C) and nuclear (N) fractions prepared from hippocampal tissue samples from two control and two MCI patients. Histone-3 (His-3) levels were also probed to confirm the purity of nuclear fractions, and GAPDH was used as a loading control. (B) Mean ± SD CP I 76/80 kDa ratios measured across all subjects. **P* < 0.01.




Fig. 2 Increased calpain-mediated truncation/activation of CN- α with MCI. (A) Western blots of CN- α and CN- β in human hippocampal brain tissue extracts incubated at 37 °C for 15 min in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of 2 mM DTT, 1 unit of recombinant pig-calpain1 (CP I) and 2 mM CaCl_2 (Ca^{2+}). (B) Representative Western blots for CN- α and CN- β in cytosolic (C) and nuclear (N) fractions prepared from hippocampal tissue samples from two control and two MCI patients. Histone-3 (His-3) levels were also probed to confirm the purity of nuclear fractions, while GAPDH was used as a loading control. (C), (D) and (E) Cytosolic and nuclear accumulation (mean \pm SD) of full-length (FL), and Δ 57 kDa and Δ 48 kDa proteolyzed fragments of CN- α measured across all subjects. * $P < 0.05$, # $P < 0.005$, + $P < 0.001$.

band represents full-length CN-A, and the 57 and 48 kDa bands could be strongly induced in human hippocampal whole tissue homogenates treated for 15 min with 1 mM Ca^{2+} and purified CP I (Fig. 2A), consistent with CP I-mediated proteolysis as shown in other reports (Wu *et al.*, 2004). The full length 60 kDa band is referred to from here out as FLCN-A, while the 57 and 48 kDa fragments are referred to as Δ CN-A57 and Δ CN-A48. Note that the 37 kDa band was not dependent on CP I activity (Fig. 2A), suggesting that this fragment is generated by another protease or perhaps represents an alternative splice variant of CN-A.

When analyzed in different subcellular fractions across subject groups, both CN- α and CN- β occurred predominantly




Fig. 3 Interrelationships between cytosolic-associated CP and CN truncation: Scatter plots showing ranked CP I levels as a function of either FLCN- α (A), Δ CN- α 57 (B) or Δ CN- α 48 (C) in hippocampal cytosolic fractions from all subjects.

as full-length proteins and no group differences were observed for FLCN- α or FLCN- β in any fraction (Fig. 2B and see Fig. S1A,B). In contrast, changes in CN proteolysis were apparent, but depended strongly on the isoform and subcellular fraction examined. For the CN- α isoform, overall Δ CN- α 48 levels were significantly higher ($P < 0.05$) in MCI subjects (Fig. 2E), due primarily to a large significant increase in the cytosolic fraction ($P < 0.01$). In fact, approximately 25% of all available cytosolic CN- α in the MCI group was of the Δ CN- α 48 variety. Moreover, within subject comparisons revealed a strong positive correlation ($r = 0.57$, $P < 0.05$) between Δ CN- α 48 and CP I in the cytosol, consistent with elevated CP-mediated proteolysis during MCI (Fig. 3C). Interestingly, Δ CN- α 48 was significantly reduced ($P < 0.001$) in the nucleus of MCI subjects (Fig. 2E). However, the absolute amounts of nuclear Δ CN- α 48 were very low for both groups ($< 10\%$ of all CN α in the nucleus). Although Δ CN- α 57 was the most abundant proteolytic fragment across cellular fractions, no differences in its levels were observed between control and MCI subjects (Fig. 2D), nor was a significant correlation observed between Δ CN- α 57 and CP I in any cellular fraction (Fig. 3B).

Unlike the CN- α isoform, total levels for CN- β proteolytic fragments (Δ CN- β 57, Δ CN- β 48 and Δ CN- β 37 kDa) exhibited high intra-group variability with no significant differences across subject groups (Fig. 2B, average data not shown). Moreover, even though CP I is capable of cleaving CN- β *in vitro* (Fig. 2A), we observed no significant correlation between CP I and any CN- β proteolytic fragment (data not shown).

Finally, because a sizable pool of CN is associated with the plasma membrane, where it is tethered to a variety of binding proteins and juxtaposed to neurotransmitter receptors and ion channels, we also investigated CN levels in membrane fractions from control and MCI subjects (Fig. S2A,B). Western blots revealed one primary band for each CN-A isoform, which appeared at similar levels in both subject groups. When analyzed side-by-side with tissue fractions that contain both full-length and proteolyzed CN (i.e., human hippocampal cytosolic and nuclear extracts, and primary rat hippocampal culture homogenates), membrane-associated CN migrated more closely with the 60 kDa product (Fig. S2C). This result suggests that membrane-associated CN exists largely as a full-length protein.

Oligomeric A β stimulates CP-dependent proteolysis and activation of CN

The results on human hippocampus suggest that CN- α undergoes significant CP-1-mediated proteolysis during the early phase of cognitive decline associated with AD (Figs 2 and 3). To further investigate CP-CN interactions in the context of AD, we quantified CN proteolysis in primary rat hippocampal cultures at 3 and 24 h after treatment with pathogenic oligomeric A β peptides alone (65 nM) or in the presence of the CP inhibitor calpeptin (10 μ M) or the caspase I inhibitor Z-YVAD-FMK (1 μ M). Cleavage of the well-characterized calpain substrate, α -spectrin, from an ~250 to an ~150 kDa product was used as a positive control for CP-dependent proteolysis. At 3 h post-A β exposure, very little proteolysis of either CN- α or spectrin was observed (Fig. 4A, top panel). However, at the 24 h time point, extensive proteolysis was observed for both of these proteins (Fig. 4B, top panel). This proteolysis was blocked by calpeptin, but not by Z-YVAD-FMK, suggesting a relatively selective role for CP in CN proteolysis.

To determine if CN proteolysis resulted in greater CN signaling, we measured the transcriptional activity of the nuclear factor of activated T cells (NFAT, a specific and well-characterized CN substrate) in separate hippocampal cultures following A β treatment. As we have shown previously in primary astrocyte cultures (Abdul *et al.*, 2009), oligomeric A β strongly stimulated NFAT activation in primary mixed cultures (Fig. 4A,B, bottom panels). And while blockade of CP activity with calpeptin markedly reduced NFAT activation by oligomeric A β , this effect was dependent on exposure time. Specifically, calpeptin had little effect within the first three hours of A β treatment (Fig. 4A, bottom panel), but reduced NFAT activity by more than 50% ($P < 0.05$) when assessed after a 24 h exposure (Fig. 4B, bottom panel). These results are consistent with the time-dependent changes observed




Fig. 4 Blockade of calpain activity inhibits A β -mediated proteolysis and activation of CN in primary hippocampal cultures. (A–B, top panels) Representative Western blots of spectrin, CN- α , and GAPDH in mixed hippocampal cultures treated 3 (A) or 24 h (B) prior with oligomeric A $\beta_{(1-42)}$ in the presence or absence of the potent CP inhibitor calpeptin (CLPT) or the caspase I inhibitor Z-YVAD-FMK (Z-YVAD). (A–B, bottom panels) Mean \pm SEM NFAT-luciferase activity (% control) in separate primary hippocampal cultures at 3 (A) and 24 h (B) after A $\beta_{(1-42)}$ treatment in the presence or absence of CLPT. (C) Immunofluorescent labeling of MAP2 in mixed hippocampal cultures 24 h after A $\beta_{(1-42)}$ treatment in the presence or absence of CLPT or FK506. * $P < 0.05$, # $P < 0.001$.

for CN proteolysis shown in the top panels of Fig. 4A,B and suggest that elevated CN signaling following A β exposure results, in part, from CP I-mediated proteolysis of the CN- α isoform.

A β peptides have been well-characterized for their deleterious effects on neuronal structure and viability, many of which are mediated through activation of CPs and CN (Jordan *et al.*, 1997; Kuwako *et al.*, 2002; Shankar *et al.*, 2007; Agostinho *et al.*, 2008; Reese *et al.*, 2008; Wei *et al.*, 2008; Tackenberg & Brandt, 2009; Lopes *et al.*, 2010; Wu *et al.*, 2010; Zhao *et al.*, 2010). Similar to these reports, we also observed striking degeneration in MAP2-labeled primary neurons exposed for 24 h to oligomeric A β peptides, including widespread dendritic blebbing and atrophy (Fig. 4C). Although these effects were greatly ameliorated by blockade of CP activity with calpeptin, signs of degeneration, in particular dendritic blebbing, were still evident. In contrast, cultures treated with A β in the presence of the CN inhibitor, FK-506 (2 μ M), appeared vibrant and healthy and were visually indis-

tinguishable from control cultures. These results suggest that A β -mediated activation of CN, through CP-dependent and independent means plays a critical role in neurodegeneration.

CP/CN interactions and NR2B proteolysis during MCI

While MCI is associated with elevated A β levels (Murphy *et al.*, 2007; Okello *et al.*, 2009), signs of extensive neurodegeneration and cell death are not usually present during this putative stage of AD. Instead, MCI is characterized by a subtle loss of synaptic contacts and/or proteins (Scheff *et al.*, 2006; Murphy *et al.*, 2007; Scheff *et al.*, 2007; Sultana *et al.*, 2010) and mild neural atrophy (Apostolova *et al.*, 2010), which may be early consequences of amyloidosis. CPs and CN regulate a wide array of proteins involved in the structural and functional organization of synapses and dendrites (Perrin & Huttenlocher, 2002; Goll *et al.*, 2003; Groth *et al.*, 2003). Some postsynaptic elements, such as NMDA receptors (NMDARs), act as a source and a target for the activation of CPs and CN (Guttmann *et al.*, 2001; Simpkins *et al.*, 2003; Yuen *et al.*, 2008). Recent evidence shows that the NR2A and NR2B subunits of the NMDA receptor complex are proteolyzed by CP through a pathway involving CN (Yuen *et al.*, 2008). As such, these proteins may show increased sensitivity to alterations in CN proteolysis during MCI.

Based on these reports, we assessed protein levels for NR2A and NR2B in membrane fractions from postmortem human hippocampus of the same control and MCI subjects used for CP/CN measurements (Figs 1–3). The ubiquitously expressed Na⁺/K⁺ ATPase was used as a loading control. As shown in Fig. 5A, we observed little if any proteolysis of the NR2A subunit, which appeared as an approximately 170 kDa band, and found no significant differences in the levels of this protein with MCI (not shown). In contrast, NR2B appeared as two primary bands with molecular weights of 180 and 115 kDa. The 115 kDa band has been characterized as a proteolytic product in other reports (Simpkins *et al.*, 2003). Relative to controls, MCI subjects exhibited a more than two-fold reduction in levels for the 180 kDa band ($P < 0.01$), but showed a $> 25\%$ increase in the 115 kDa band ($P = 0.05$, Fig. 5B), suggesting an increase in NR2B proteolysis with MCI. Indeed, 85% of all membrane-associated NR2B was in the form of the 115 kDa product for the MCI subjects, compared to 61% in the control group ($P < 0.01$, see Fig. 5B inset). Interestingly, the 115 kDa band appeared at much lower levels in hippocampal synaptosomes, whether isolated from MCI or control subjects, suggesting that proteolysis may be more characteristic of extrasynaptic NR2B subunits (Fig. 5C). To determine if human NR2B is proteolyzed by CP I *in vitro*, we picked membrane samples from two control subjects that exhibited very little NR2B proteolysis and incubated them for 15 min in sample buffer with or without 1 mM Ca²⁺ and purified CP I. The results confirmed that NR2B is indeed vulnerable to CP-mediated proteolysis (Fig. 5D). Furthermore, the extent of NR2B proteolysis shown in Fig. 5A,B significantly correlated with levels for activated CP I (i.e., 76 kDa) and Δ CN-A α 48 in cytosolic fractions prepared from the same subjects (Fig. 5E,F). Additional

studies on rat hippocampal cultures showed that NR2B undergoes proteolysis ($P < 0.01$) during prolonged (24 h) exposure to oligomeric A β peptides (Fig. 6). This proteolysis was reduced ($P < 0.05$) by co-application of the CP inhibitor, calpeptin (10 μ M) or a membrane-soluble CN auto-inhibitory peptide (10 μ M). Together, these results suggest that changes in CP I and CN regulation help drive alterations in NR2B proteolysis during MCI and/or A β pathology.

Discussion

CPs and isoform-specific changes in CN proteolysis with MCI

Of all the Ca²⁺ sensitive proteins, CPs are perhaps most consistently linked to deleterious changes in neuronal function and viability due to injury and/or chronic disease. Here, we found that activated CP I levels are elevated in human hippocampus during MCI, demonstrating that CP alterations shown previously in AD tissue (Saito & Nixon, 1993; Liu *et al.*, 2005) arise early in disease progression. These results are consistent with numerous other studies that have proposed a causative role for CPs in AD (Kuwako *et al.*, 2002; Trinchese *et al.*, 2008; Nimmerich *et al.*, 2010). CPs can initiate degenerative processes through actions on a variety of substrates, including cytoskeletal proteins and membrane receptors, to name a few (Nixon, 2003; Bertipaglia & Carafoli, 2007; Vosler *et al.*, 2008). In addition, CP is increasingly recognized as a critical regulator of CN-mediated neuronal dysfunction in several disorders (Wu *et al.*, 2007; Qu *et al.*, 2010). CP-directed removal or shortening of the CN autoinhibitory domain, located in the C-terminus of the CN-A subunit, can generate CN fragments with constitutively high basal activity (Tallant *et al.*, 1988; Wang *et al.*, 1989; Wu *et al.*, 2004). Recent studies have reported significant proteolysis and activation of CN in cortical tissue of humans with severe AD (Liu *et al.*, 2005; Wu *et al.*, 2010). These proteolytic changes may have been underestimated in earlier studies due to the use of C-terminus directed antibodies that do not detect most CN-A proteolytic fragments (Billingsley *et al.*, 1994; Ladner *et al.*, 1996; Lian *et al.*, 2001). Using an N-terminus antibody, we observed isoform and subcellular specific elevations in CN proteolysis in MCI hippocampus. In particular, the Δ CN-A α 48 fragment made up more than 25% of the total CN-A α available in the cytosol of MCI subjects and appeared in conjunction with elevated CP I levels. Why CN-A α , but not CN-A β , undergoes elevated proteolysis with MCI is unclear. Few studies have directly investigated expressional differences between these isoforms in brain, and even fewer have focused on their functional differences. In healthy rat brain tissue, CN-A α appears to be more abundantly expressed in area CA1 than in the dentate, while CN-A β shows a more even distribution across subregions (Kuno *et al.*, 1992). It is possible that these expressional differences could govern the exposure of each isoform to CP and other proteases. CPs or other proteases may also bind CN-A β with lesser affinity, and/or catalyze proteolysis with reduced efficiency. Regardless, this is the second




Fig. 5 Proteolysis of NR2B is increased during MCI and correlated to activated CPI and Δ CN-A α 48 levels. (A) Representative Western blots of NR2A and NR2B in human hippocampal membrane fractions from 10 control and 10 MCI subjects. (B) Mean \pm SD NR2B levels in human hippocampal membrane fractions across all subjects. Note that data are from the same subjects used for CP and CN measures shown in Figs 1 and 2. Inset shows the levels of the 115 kDa NR2B proteolytic fragment relative to total NR2B levels (expressed as % of total NR2B) for the same membrane fractions (C) Representative Western blots of NR2B and PSD-95 in hippocampal synaptosomal fractions from three control and three MCI patients (D) Western blot of NR2B in human hippocampal membrane fractions digested in the presence or absence of Ca^{2+} and recombinant pig-calpain1 (CP I). (E–F) Scatter plots showing ranked proteolytic levels for NR2B in human hippocampal membrane fractions relative to ranked CPI (E) and Δ CN-A α 48 levels (F) measured in the cytosolic fractions of the same subjects (see Figs 1 and 2). * $P < 0.01$.




Fig. 6 CP/CN-dependent proteolysis of NR2B in mixed hippocampal cultures treated with oligomeric A β . Top panel shows representative Western blot (top) of NR2B in individual mixed hippocampal cultures, and the bottom panel shows the average extent (mean \pm SD) of NR2B proteolysis (115 kDa band expressed as percent of total NR2B) measured in all cultures treated with oligomeric A $\beta_{(1-42)}$ in the presence or absence of the CP inhibitor, calpeptin (CLPT), or the CN autoinhibitory peptide (AIP). CT refers to control (untreated) cells. * $P < 0.05$; # $P < 0.01$.

recent study from our group that has found changes in CN-A α , but not CN-A β with MCI or AD (Abdul *et al.*, 2009), suggesting that CN-A α has greater relevance to disease progression.

Implications of CN proteolysis for progression of AD

When overexpressed in experimental models, Δ CN-A α 48 has been shown to recapitulate numerous biobehavioral markers of aging and AD including synaptic impairments (Mansuy *et al.*, 1998; Winder *et al.*, 1998), dendritic atrophy (Wu *et al.*, 2010), Ca^{2+} dysregulation (Norris *et al.*, 2010), and glial activation/neuroinflammation (Norris *et al.*, 2005). Moreover, CN inhibitors reduce memory deficits in AD mouse models (Dineley *et al.*, 2007; Tagliatela *et al.*, 2009) and negate many of the neurotoxic actions of A β (Chen *et al.*, 2002; Cardoso & Oliveira, 2005; Snyder *et al.*, 2005; Shankar *et al.*, 2007; Reese *et al.*, 2008; Abdul *et al.*, 2009; Li *et al.*, 2009; Wu *et al.*, 2010). It is noteworthy that Δ CN-A α 48 is also found at elevated levels in late stage AD (Wu *et al.*, 2010). However, unlike in MCI, this increase is more prominent in nuclear, than in cytosolic fractions. Nuclear localization of CN may reflect a more toxic stage

of Ca^{2+} dysregulation involving NFAT3-mediated transcriptional regulation (Abdul *et al.*, 2010). Our previous research (Abdul *et al.*, 2009) and work by Wu *et al.* (2010) showed that elevated nuclear levels of CN in late stage AD are strongly associated with increased nuclear NFAT3 levels. In animal models of injury, NFAT3 activation has been linked to neuronal death via induction of the Fas ligand (Shioda *et al.*, 2007; Luoma & Zirpel, 2008), whereas NFAT inhibition preserves dendritic integrity following exposure to A β (Wu *et al.*, 2010). Combined with the findings of the present study, these observations suggest that the generation of excessive $\Delta\text{CN-A}\alpha 48$ in MCI is a critical change that may set off a host of other deleterious processes resulting in widespread neurodegeneration and dementia.

A β , CP/CN interactions, and NMDARs

Soluble oligomeric A β peptides, which are elevated during MCI (Murphy *et al.*, 2007; Abdul *et al.*, 2009; Okello *et al.*, 2009), cause profound Ca^{2+} dysregulation (Green & LaFerla, 2008) and stimulate CPs and CN in a variety of cell types (Cardoso & Oliveira, 2005; Reese *et al.*, 2008; Abdul *et al.*, 2009; Wu *et al.*, 2010). The present work suggests that A β -mediated activation of neurotoxic CN signaling partly results from extensive CP-directed proteolysis of the CN-A α isoform. However, while CP and CN inhibitors each reduced neuronal degeneration in response to A β , CN inhibitors appeared to confer greater protection. As mentioned, FLCN is exquisitely sensitive to Ca^{2+} and might be expected to show rapid and direct activation in response to A β -dependent Ca^{2+} elevations with or without CP activation. In fact, CP inhibitors were much more effective at inhibiting CN proteolysis and signaling over a 24 h period than within the first few hours of A β exposure. The initial A β -dependent increase in FLCN-A activity may therefore be sufficient to initiate degenerative processes, while CP-mediated proteolysis of CN exacerbates and/or perpetuates these processes. Regardless, these findings strongly suggest that CP and CN activation are not discrete outcomes of elevated A β , but instead are part of a common pathway involved in neurotoxicity.

Changes in CP/CN interactions during MCI appear to be intertwined with NMDARs, which are the primary target of memantine, an FDA-approved drug used in the treatment of AD (Parsons *et al.*, 2007). Our results demonstrate a selective increase in the proteolysis of NR2B-type NMDARs with MCI concurrent with elevated CP and $\Delta\text{CN-A}\alpha 48$ levels. Similar proteolysis of NR2B was induced in rat hippocampal cultures by A β and was reduced by co-application of CP and CN inhibitors. These results are generally consistent with a recent study that observed CP/CN-dependent proteolysis of NR2B in primary cortical neuron cultures (Yuen *et al.*, 2008). That we observed little proteolysis of NR2B in human hippocampal synaptosomes suggests that extrasynaptic NMDARs are a more likely target of elevated CP/CN signaling (at least, in regard to MCI and AD). This selectivity may have important functional implications as extrasynaptic NMDARs appear to play a greater role in neuronal degeneration (Hardingham *et al.*, 2002; Xu *et al.*, 2009),

particularly after exposure to A β (Ronicke *et al.*, 2010). Moreover, a recent report indicates that memantine preferentially acts at extrasynaptic as opposed to synaptically localized NMDARs (Xia *et al.*, 2010). How CP-mediated proteolysis of extrasynaptic NR2B affects neurologic function in MCI is unclear. While proteolysis may help exacerbate NMDAR-mediated toxicity, it's also possible that CP/CN interactions provide a negative feedback mechanism to dampen NMDAR activity during Ca^{2+} dysregulation (Yuen *et al.*, 2008). Clearly, further work will be necessary to distinguish between these possibilities.

Role for other proteases in CN proteolysis during MCI and AD?

Caspases are another class of proteases that are strongly implicated in neurodegenerative processes associated with AD and amyloidosis (Cotman *et al.*, 2005), with several family members showing increased expression/activity during MCI (Albrecht *et al.*, 2007; Sultana *et al.*, 2010). Similar to CPs, caspases have been shown to proteolyze CN *in vitro* and *in vivo* (Mukerjee *et al.*, 2000, 2001). However, the present study revealed little to no effect of the caspase inhibitor, Z-YVAD-FMK, on A β -mediated proteolysis of CN in primary hippocampal cultures. Nonetheless, even though our data demonstrate a close relationship between CPs and CN in human hippocampus, they do not rule out the possibility that caspases or other proteases, interact with CN and/or contribute to altered CN proteolysis during MCI.

Summary and conclusions

The Ca^{2+} hypothesis of aging and AD, proposed more than 25 years ago (Khachaturian, 1984; Landfield & Pitler, 1984; Gibson & Peterson, 1987), has been supported by abundant evidence obtained from multiple experimental models using diverse experimental approaches (Canzoniero & Snider, 2005; Bezprozvanny & Mattson, 2008; Green & LaFerla, 2008; Small, 2009). However, the present study is among the relatively few to directly link changes in Ca^{2+} regulation to the early stages of AD progression. Our results suggest that increased CN signaling observed previously during MCI (Abdul *et al.*, 2009) and in multiple animal models of AD and amyloidosis (Dineley *et al.*, 2007; Kuchibhotla *et al.*, 2008; Wu *et al.*, 2010) may arise from CP-mediated proteolysis of the CN-A α isoform. Disrupting the structural and/or functional interaction of CPs and CN offers a promising novel approach for treating AD and other neurodegenerative disorders.

Experimental procedures

Subjects

Post-mortem brain samples from the hippocampus and cerebellum were provided by the Neuropathology Core of the Alzheimer's Disease Center (ADC) at the University of Kentucky. Specimens from the hippocampus were obtained at autopsy

and snap-frozen in liquid nitrogen. Hippocampus of 10 MCI and 10 age-matched cognitively unimpaired subjects were used for this study (Table 1). All subjects were participants in the University of Kentucky's ADC Autopsy program. At autopsy (~3 h after death), tissue from multiple brain regions was processed for neuropathological evaluations as described elsewhere (Nelson *et al.*, 2007).

Preparation of cell extracts from human brain tissue

Autopsied human brain tissue samples were flash-frozen in liquid nitrogen and stored at -80°C until use. Membrane, cytosolic and nuclear fractions from hippocampal tissue samples were prepared as described previously (Abdul *et al.*, 2009). The membrane fractions obtained were resuspended in sucrose buffer [in mM: 300 sucrose, 75 NaCl, 10 Tris (pH 7.4), 20 EDTA, 20 EGTA] containing phosphatase, protease, and CP inhibitor cocktails (EMD Chemicals, Gibbstown, NJ, USA). Cytosolic and nuclear fractions were resuspended in buffer C [in mM: 50 HEPES (pH 7.6), 50 KCl, 0.1 EDTA, 10% glycerol, 1 dithiothreitol (DTT)], containing phosphatase, protease, and CP inhibitor cocktails and stored at -80°C until use.

In vitro proteolysis of CN by calpain1

Human whole brain extracts were prepared in HEPES homogenizing buffer (pH 7.5) with phosphatase inhibitor. The extracts were incubated in the presence of Ca^{2+} (1 mM), DTT (5 mM) and/or recombinant Pig calpain 1 (1 Unit) for 15 min at 37°C . The reactions were terminated by addition of 2 \times concentrated SDS-PAGE sample buffer. The samples were boiled in water for 5 min and the products of proteolysis were analyzed by Western blots, probing with antibodies to CN-A α , CN-A β and GAPDH (loading control).

Synaptosome preparation

Synaptosome fractions from control and MCI human hippocampus were isolated as described previously (Mohammad Abdul & Butterfield, 2005). In brief, hippocampal tissue was homogenized in isolation buffer (in mM: 320 sucrose, 0.2 PMSF, 2 EDTA, 2 EGTA, 20 HEPES, 4 $\mu\text{g mL}^{-1}$ leupeptin, 4 $\mu\text{g mL}^{-1}$ pepstatin, 5 $\mu\text{g mL}^{-1}$ aprotinin, and 20 $\mu\text{g mL}^{-1}$ trypsin inhibitor) and centrifuged at 1940 *g* for 10 min at 0°C . The supernatant was collected and centrifuged at 25 400 *g* for 12 min at 0°C . The resulting pellet was mixed with a small volume of cold isolation buffer and layered onto cold discontinuous sucrose gradients containing 10 mL each of 1.18 M (pH 8.5), 1.0 M (pH 8.0), and 0.85 M (pH 8.0) sucrose, as well as 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES. Gradients were centrifuged in a Beckman–Coulter Optima L-90K ultracentrifuge at 82 500 *g* for 1 h at 4°C . Resulting purified synaptosomes were removed from the 1.18/1.0 M interface and washed three times in Locke's buffer (in mM: 0.15 NaCl, 5.6 KCl, 2.3 CaCl_2 , 1.0 MgCl_2 , 3.6 NaHCO_3 , 5.0 Glucose, and 5.0 HEPES; pH 7.4) at 29 100 *g* for 12 min at 0°C .

Primary cell culture

Primary mixed (neurons and astrocytes) hippocampal cultures were prepared from embryonic day 18 Sprague–Dawley rat pups as described previously (Sama *et al.*, 2008). Cells were investigated at between 14 and 21 days *in vitro*.

Western blot analysis

Western blots of *postmortem* human tissue and primary cell cultures were performed using ECL Plus reagents (Amersham, Piscataway, NJ, USA) as described previously (Norris *et al.*, 2005; Sama *et al.*, 2008; Abdul *et al.*, 2009). Primary antibodies used include: 1:3000 anti-CN-A α or 1:3000 anti-CN-A β (EMD Biochemicals, Gibbstown, NJ, USA), 1:10 000 anti-histone3 (Sigma-Aldrich, Saint Louis, MO, USA), 1:10 000 anti-calpain1 or 1:10 000 anti-Na $^{+}$ -K $^{+}$ -ATPase (Abcam, Cambridge, MA, USA) or 1:1000 anti-NR2A/NR2B (Millipore, Billerica, MA, USA), 1:10 000 anti-spectrin-A β 38 (Abcam).

Oligomeric A β treatment of primary hippocampal cultures

Synthetic oligomeric A β (65 nm) prepared as previously described (Abdul *et al.*, 2009) was delivered to cell cultures in the presence or absence of the following inhibitors (from EMD, Gibbstown, NJ, USA): calpeptin (10 μM), FK-506 (3 μM), CN autoinhibitory peptide (10 μM), and Z-YVAD-FMK (1 μM). All inhibitors were added 2 h prior to oligomeric A $\beta_{(1-42)}$ treatments. Western blots, NFAT luciferase activity assays, and/or immunofluorescent labeling were then performed 3 or 24 h later using our previously published methods (Sama *et al.*, 2008; Abdul *et al.*, 2009; Furman *et al.*, 2010). For immunofluorescent labeling of MAP2-positive neurons, ten 40 \times fields of cells were chosen at random within each condition and cell fluorescence was imaged using a Nikon CoolSnap ES digital camera (Photometrics, Tucson, AZ, USA).

NFAT activity assays

Methods for eliciting and measuring NFAT-dependent transcriptional activation in primary cultures were very similar to those used previously by our group (Sama *et al.*, 2008; Abdul *et al.*, 2009; Furman *et al.*, 2010). At approximately 24 h before treatment with oligomeric A β , 35 mm hippocampal culture dishes were infected (at a multiplicity of infection of 100) with recombinant adenovirus encoding an NFAT-dependent luciferase reporter construct (Ad-NFAT-Luc), provided by Dr Jeff Molkenin at the University of Cincinnati. Ad-NFAT-luc encodes nine copies of an NFAT binding site (from the IL-4 promoter) and an additional minimal promoter upstream of a luciferase sequence, and has been described elsewhere (Wilkins *et al.*, 2004). In our experience, transgene expression is achieved in $\geq 90\%$ of all astrocytes and 60–70% of all neurons in mixed hippocampal cultures when adenovirus is used at an MOI of 50 or more. At either 3 or 24 h

after exposure to oligomeric A β , each culture dish was washed three times in PBS and cells were scraped free and pelleted at 27 000 g. Supernatants from each 35 mm dish were removed and replaced with CAT buffer (250 mM Tris pH 8.0, 1 mM EDTA) and pellets were stored at -20°C until use. Samples were freeze/thawed twice, re-suspended, centrifuged at 13 000 rpm, and supernatants collected. To control for potential between-group variability in NFAT-luciferase expression, all sample volumes were normalized to the same protein concentration using the Lowry method. Luciferase expression was quantified using a luciferase detection kit (luc Screen; Tropix, Bedford, MA, USA) and a plate reader. Typically, six or more dishes were analyzed per treatment condition, resulting in a well-powered experimental design.

Statistical analysis

Unless otherwise stated, all results are expressed as means \pm SD. Analysis of variance (ANOVA), followed by Fischer's PLSD *post hoc* test, was used for almost all statistical comparisons. For within-subject correlational analyses, each subject (regardless of diagnosis) was ranked in ascending order (from one to 20) on the basis of protein expression levels for each target protein (e.g. CP I, CN A α 48 kDa, and NR2B) as determined by Western blot. Ranked values for any two target proteins were then compared using a simple regression analysis. Subjects used for these analyses were the same ones used to generate average group data shown in Figs 1, 2, and 5. Differences were considered significant at $P < 0.05$.

Acknowledgments

This work was supported by National Institutes of Health Grants AG024190, AG027297, AG028383, and AG010836 and a gift from the Kleberg Foundation.

Author contributions

HMA Performed experiments, prepared manuscript. IB Produced oligomeric Abeta peptides. HL III provided oligomeric Abeta peptides; provided guidance for executing Abeta experiments. RPG provided calpain antibodies; provided expertise on proteolysis experiments and helped interpret proteolytic products in Western blots. CMN supervised project; prepared manuscript.

References

Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H 3rd, Kraner SD, Norris CM (2009) Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. *J. Neurosci.* **29**, 12957–12969.

Abdul HM, Furman JL, Sama MA, Mathis DM, Norris CM (2010) NFATs and Alzheimer's disease. *Mol. Cell Pharmacol.* **2**, 7–14.

Agostinho P, Lopes JP, Velez Z, Oliveira CR (2008) Overactivation of calcineurin induced by amyloid-beta and prion proteins. *Neurochem. Int.* **52**, 1226–1233.

Albrecht S, Bourdeau M, Bennett D, Mufson EJ, Bhattacharjee M, LeBlanc AC (2007) Activation of caspase-6 in aging and mild cognitive impairment. *Am. J. Pathol.* **170**, 1200–1209.

Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, Mistur R, Tsui WH, de Leon MJ (2010) Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. *Neurobiol. Aging* **31**, 1077–1088.

Bertipaglia I, Carafoli E (2007) Calpains and human disease. *Subcell. Biochem.* **45**, 29–53.

Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. *Trends Neurosci.* **31**, 454–463.

Billingsley ML, Ellis C, Kincaid RL, Martin J, Schmidt ML, Lee VM, Trojanowski JQ (1994) Calcineurin immunoreactivity in Alzheimer's disease. *Exp. Neurol.* **126**, 178–184.

Canzoniero LM, Snider BJ (2005) Calcium in Alzheimer's disease pathogenesis: too much, too little or in the wrong place? *J. Alzheimers Dis.* **8**, 147–154; discussion 209–115.

Cardoso SM, Oliveira CR (2005) The role of calcineurin in amyloid-beta-peptides-mediated cell death. *Brain Res.* **1050**, 1–7.

Chen QS, Wei WZ, Shimahara T, Xie CW (2002) Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. *Neurobiol. Learn. Mem.* **77**, 354–371.

Cotman CW, Poon WW, Rissman RA, Blurton-Jones M (2005) The role of caspase cleavage of tau in Alzheimer disease neuropathology. *J. Neuropathol. Exp. Neurol.* **64**, 104–112.

Dineley KT, Hogan D, Zhang WR, Taglialetta G (2007) Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. *Neurobiol. Learn. Mem.* **88**, 217–224.

Furman JL, Artiushin IA, Norris CM (2010) Disparate effects of serum on basal and evoked NFAT activity in primary astrocyte cultures. *Neurosci. Lett.* **469**, 365–369.

Gibson GE, Peterson C (1987) Calcium and the aging nervous system. *Neurobiol. Aging* **8**, 329–343.

Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. *Physiol. Rev.* **83**, 731–801.

Green KN, LaFerla FM (2008) Linking calcium to Abeta and Alzheimer's disease. *Neuron* **59**, 190–194.

Groth RD, Dunbar RL, Mermelstein PG (2003) Calcineurin regulation of neuronal plasticity. *Biochem. Biophys. Res. Commun.* **311**, 1159–1171.

Guttmann RP, Baker DL, Seifert KM, Cohen AS, Coulter DA, Lynch DR (2001) Specific proteolysis of the NR2 subunit at multiple sites by calpain. *J. Neurochem.* **78**, 1083–1093.

Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat. Neurosci.* **5**, 405–414.

Huang W, Fileta J, Rawe I, Qu J, Grosskreutz CL (2010) Calpain activation in experimental glaucoma. *Invest. Ophthalmol. Vis. Sci.* **51**, 3049–3054.

Jordan J, Galindo MF, Miller RJ (1997) Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. *J. Neurochem.* **68**, 1612–1621.

Khachaturian ZS (1984) Towards theories of brain aging. In *Handbook of Studies on Psychiatry and Old Age* (Kay DW, Burrows GW, eds). Amsterdam: Elsevier, pp. 7–30.

Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacsikai BJ (2008) Abeta plaques lead to aberrant regulation of calcium

- homeostasis *in vivo* resulting in structural and functional disruption of neuronal networks. *Neuron* **59**, 214–225.
- Kuno T, Mukai H, Ito A, Chang CD, Kishima K, Saito N, Tanaka C (1992) Distinct cellular expression of calcineurin A alpha and A beta in rat brain. *J. Neurochem.* **58**, 1643–1651.
- Kuwako K, Nishimura I, Uetsuki T, Saido TC, Yoshikawa K (2002) Activation of calpain in cultured neurons overexpressing Alzheimer amyloid precursor protein. *Brain Res. Mol. Brain Res.* **107**, 166–175.
- Ladner CJ, Czech J, Maurice J, Lorens SA, Lee JM (1996) Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. *J. Neuropathol. Exp. Neurol.* **55**, 924–931.
- Landfield PW, Pitler TA (1984) Prolonged Ca^{2+} -dependent afterhyperpolarizations in hippocampal neurons of aged rats. *Science* **226**, 1089–1092.
- Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. *Neuron* **62**, 788–801.
- Lian Q, Ladner CJ, Magnuson D, Lee JM (2001) Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. *Exp. Neurol.* **167**, 158–165.
- Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX (2005) Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. *J. Biol. Chem.* **280**, 37755–37762.
- Lopes JP, Oliveira CR, Agostinho P (2010) Neurodegeneration in an Abeta-induced model of Alzheimer's disease: the role of Cdk5. *Aging Cell* **9**, 64–77.
- Luoma JI, Zirpel L (2008) Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. *J. Neurosci.* **28**, 3159–3169.
- Mansuy IM, Winder DG, Moallem TM, Osman M, Mayford M, Hawkins RD, Kandel ER (1998) Inducible and reversible gene expression with the rtTA system for the study of memory. *Neuron* **21**, 257–265.
- Marcum JL, Mathenia JK, Chan R, Guttman RP (2005) Oxidation of thiol-proteases in the hippocampus of Alzheimer's disease. *Biochem. Biophys. Res. Commun.* **334**, 342–348.
- Mohammad Abdul H, Butterfield DA (2005) Protection against amyloid beta-peptide (1–42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. *Biochim. Biophys. Acta* **1741**, 140–148.
- Mukerjee N, McGinnis KM, Park YH, Gnegy ME, Wang KK (2000) Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells. *Arch. Biochem. Biophys.* **379**, 337–343.
- Mukerjee N, McGinnis KM, Gnegy ME, Wang KK (2001) Caspase-mediated calcineurin activation contributes to IL-2 release during T cell activation. *Biochem. Biophys. Res. Commun.* **285**, 1192–1199.
- Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H 3rd, Keller JN (2007) Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. *Neurobiol. Dis.* **27**, 301–311.
- Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiola MS, Abner EL, Markesbery WR (2007) Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. *J. Neuropathol. Exp. Neurol.* **66**, 1136–1146.
- Nimmrich V, Reymann KG, Strassburger M, Schoder UH, Gross G, Hahn A, Schoemaker H, Wicke K, Moller A (2010) Inhibition of calpain prevents NMDA-induced cell death and beta-amyloid-induced synaptic dysfunction in hippocampal slice cultures. *Br. J. Pharmacol.* **159**, 1523–1531.
- Nixon RA (2003) The calpains in aging and aging-related diseases. *Ageing Res. Rev.* **2**, 407–418.
- Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Landfield PW, Kraner SD (2005) Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. *J. Neurosci.* **25**, 4649–4658.
- Norris CM, Blalock EM, Chen KC, Porter NM, Thibault O, Kraner SD, Landfield PW (2010) Hippocampal ‘zipper’ slice studies reveal a necessary role for calcineurin in the increased activity of L-type Ca^{2+} channels with aging. *Neurobiol. Aging* **31**, 328–338.
- Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Brooks DJ (2009) Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. *Neurology* **72**, 56–62.
- Parsons CG, Stoffer A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. *Neuropharmacology* **53**, 699–723.
- Perrin BJ, Huttenlocher A (2002) Calpain. *Int. J. Biochem. Cell Biol.* **34**, 722–725.
- Qu J, Wang D, Grosskreutz CL (2010) Mechanisms of retinal ganglion cell injury and defense in glaucoma. *Exp. Eye Res.* **91**, 48–53.
- Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH, Campbell J, Chen Y, Jiang Y, Paskevich PA, Cataldo AM, Haroutunian V, Nixon RA (2008) Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. *J. Neurosci.* **28**, 12241–12254.
- Reese LC, Zhang W, Dineley KT, Kaye R, Taglialetta G (2008) Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. *Aging Cell* **7**, 824–835.
- Ronicke R, Mikhaylova M, Ronicke S, Meinhardt J, Schroder UH, Fandrich M, Reiser G, Kreutz MR, Reymann KG (2010) Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. *Neurobiol. Aging*. (ahead of print).
- Saito K, Nixon RA (1993) Specificity of calcium-activated neutral proteinase (CANP) inhibitors for human mu CANP and mCANP. *Neurochem. Res.* **18**, 231–233.
- Saito K, Elce JS, Hamos JE, Nixon RA (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. *Proc. Natl. Acad. Sci. USA* **90**, 2628–2632.
- Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD, Norris CM (2008) Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. *J. Biol. Chem.* **283**, 21953–21964.
- Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. *Neurobiol. Aging* **27**, 1372–1384.
- Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. *Neurology* **68**, 1501–1508.
- See V, Loeffler JP (2001) Oxidative stress induces neuronal death by recruiting a protease and phosphatase-gated mechanism. *J. Biol. Chem.* **276**, 35049–35059.
- Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J. Neurosci.* **27**, 2866–2875.

- Shioda N, Moriguchi S, Shirasaki Y, Fukunaga K (2006) Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. *J. Neurochem.* **98**, 310–320.
- Shioda N, Han F, Moriguchi S, Fukunaga K (2007) Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. *J. Neurochem.* **102**, 1506–1517.
- Simpkins KL, Guttman RP, Dong Y, Chen Z, Sokol S, Neumar RW, Lynch DR (2003) Selective activation induced cleavage of the NR2B subunit by calpain. *J. Neurosci.* **23**, 11322–11331.
- Small DH (2009) Dysregulation of calcium homeostasis in Alzheimer's disease. *Neurochem. Res.* **34**, 1824–1829.
- Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. *Nat. Neurosci.* **8**, 1051–1058.
- Sultana R, Banks WA, Butterfield DA (2010) Decreased levels of PSD95 and two associated proteins and increased levels of BCL2 and caspase 3 in hippocampus from subjects with amnesic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of A β , and neurodegeneration in a prodromal stage of Alzheimer's disease. *J. Neurosci. Res.* **88**, 469–477.
- Tackenberg C, Brandt R (2009) Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. *J. Neurosci.* **29**, 14439–14450.
- Taglialetela G, Hogan D, Zhang WR, Dineley KT (2009) Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. *Behav. Brain Res.* **200**, 95–99.
- Tallant EA, Brumley LM, Wallace RW (1988) Activation of a calmodulin-dependent phosphatase by a Ca²⁺-dependent protease. *Biochemistry* **27**, 2205–2211.
- Thibault O, Gant JC, Landfield PW (2007) Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. *Aging Cell* **6**, 307–317.
- Toescu EC, Verkhatsky A (2007) The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. *Aging Cell* **6**, 267–273.
- Toescu EC, Verkhatsky A, Landfield PW (2004) Ca(2+) regulation and gene expression in normal brain aging. *Trends Neurosci.* **27**, 614–620.
- Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA, Arancio O (2008) Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. *J. Clin. Invest.* **118**, 2796–2807.
- Vaisid T, Kosower NS, Katzav A, Chapman J, Barnoy S (2007) Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. *Neurochem. Int.* **51**, 391–397.
- Veeranna, Kaji T, Boland B, Odrilj T, Mohan P, Basavarajappa BS, Peterhoff C, Cataldo A, Rudnicki A, Amin N, Li BS, Pant HC, Hungund BL, Arancio O, Nixon RA (2004) Calpain mediates calcium-induced activation of the erk1, 2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. *Am. J. Pathol.* **165**, 795–805.
- Vosler PS, Brennan CS, Chen J (2008) Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. *Mol. Neurobiol.* **38**, 78–100.
- Wang KK, Roufogalis BD, Villalobo A (1989) Characterization of the fragmented forms of calcineurin produced by calpain I. *Biochem. Cell Biol.* **67**, 703–711.
- Wei Z, Song MS, MacTavish D, Jhamandas JH, Kar S (2008) Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons. *Neuropharmacology* **54**, 721–733.
- Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. *Circ. Res.* **94**, 110–118.
- Winder DG, Mansuy IM, Osman M, Moallem TM, Kandel ER (1998) Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin. *Cell* **92**, 25–37.
- Wu HY, Tomizawa K, Oda Y, Wei FY, Lu YF, Matsushita M, Li ST, Moriwaki A, Matsui H (2004) Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. *J. Biol. Chem.* **279**, 4929–4940.
- Wu HY, Tomizawa K, Matsui H (2007) Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. *Acta Med. Okayama* **61**, 123–137.
- Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spire-Jones T, Xie H, Arbel-Ornath M, Grosskreutz CL, Bacsai BJ, Hyman BT (2010) Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. *J. Neurosci.* **30**, 2636–2649.
- Xia P, Chen HS, Zhang D, Lipton SA (2010) Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. *J. Neurosci.* **30**, 11246–11250.
- Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, Baum ML, Bibb JA, Lombroso PJ (2009) Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. *J. Neurosci.* **29**, 9330–9343.
- Yuen EY, Ren Y, Yan Z (2008) Postsynaptic density-95 (PSD-95) and calcineurin control the sensitivity of N-methyl-D-aspartate receptors to calpain cleavage in cortical neurons. *Mol. Pharmacol.* **74**, 360–370.
- Zhao WQ, Santini F, Breese R, Ross D, Zhang XD, Stone DJ, Ferrer M, Townsend M, Wolfe AL, Seager MA, Kinney GG, Shughrue PJ, Ray WJ (2010) Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. *J. Biol. Chem.* **285**, 7619–7632.

Supporting Information

Additional supporting information may be found in the online version of this article:

Fig. S1 Representative Western blots for CN-A α (A) and CN-A β (B) in cytosolic (C) and nuclear (N) fractions prepared from hippocampal tissue samples from two control and two MCI subjects.

Fig. S2 (A and B, top panels) Representative Western blots for membrane-associated CN-A α (A) and CN-A β (B) in cytosolic (C) and nuclear (N) fractions prepared from hippocampal tissue samples from two control and two MCI subjects.

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.